Sort   by:  
 Page size 
UnknownCRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.

Background

CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among them, cytokines with an inhibitory impact on the imm...
S-EPMC8627098 | biostudies-literature
UnknownCIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy.
The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontie...
S-EPMC6343606 | biostudies-literature
UnknownCIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Not available
S-EPMC5137546 | biostudies-literature
UnknownCIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Not available
S-EPMC4962731 | biostudies-literature
Sort   by:  
 Page size